Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19066248 | 0.84 | ADORA1 (0.49) | ADORA1ADORA2ALMNAGAAMAPK10 | |
| SCHEMBL4905051 | 0.76 | ADORA1 (0.48) | ADORA1ADORA2ALMNAGAAMAPK10 | |
| SCHEMBL15156677 | 0.74 | DHFR (0.54) | ADORA1ADORA2ALMNAGAAMAPK10 | |
| SCHEMBL14726402 | 0.72 | ADORA1 (0.56) | ADORA1ADORA2AGFERKMT2ADHFR | |
| SCHEMBL1317365 | 0.71 | DHFR (0.66) | ADORA1ADORA2AGFERKMT2ADHFR | |
| SCHEMBL30453734 | 0.71 | DHFR (0.66) | ADORA1ADORA2AGFERKMT2ADHFR | |
| SCHEMBL4582424 | 0.70 | ADORA1 (0.83) | ADORA1ADORA2AGFERKMT2AMAPT | |
| Hydrochloric Acid SCHEMBL1091696 | 0.70 | DHFR (0.64) | ADORA1ADORA2AGFERKMT2ADHFR | |
| Hydrochloric Acid SCHEMBL12813248 | 0.70 | DHFR (0.64) | ADORA1ADORA2AGFERKMT2ADHFR | |
| SCHEMBL27545354 | 0.69 | L3MBTL1 (0.38) | LMNAKMT2AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | ADORA1 680/4885ADORA2A 560/4885LMNA 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.